Sign up for our FREE GI E-Weekly for more coverage like this sent to your inbox!
LT-02 is designed to treat ulcerative colitis by improving the barrier function of the colon through a delayed release formula.
The company intends to move forward with the Phase III trial of LT-02 in ulcerative colitis patients.
More Articles on Gastroenterology:
Olympus Surgical Video System Receives FDA 510(k) Clearance
8 Gastroenterology Devices Receive FDA 510(k) Clearance in March
American Cancer Society Awards Dr. Stephen Meltzer Research Grant
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
